Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Diabetes Technology Meeting 2020 - Trisha Shang, Jennifer Y. Zhang, B. Wayne Bequette, Jennifer K. Raymond, Gerard Coté, Jennifer L. Sherr, Jessica Castle, John Pickup, Yarmela Pavlovic, Juan Espinoza, Laurel H. Messer

FreeStyle Libre Continuous Glucose Monitoring

dxcm-20201231

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Freestyle Libre 2 - Continuous Glucose Monitoring System

PDF) Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations

FreeStyle Libre Continuous Glucose Monitoring

Diabetes unit continues to power growth at Abbott

FreeStyle Libre 2 System (CGM)

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

FreeStyle Libre 2 Continuous Glucose Monitor